Success Metrics

Clinical Success Rate
75.0%

Based on 3 completed trials

Completion Rate
75%(3/4)
Active Trials
0(0%)
Results Posted
33%(1 trials)
Terminated
1(25%)

Phase Distribution

Ph phase_4
1
25%
Ph phase_2
1
25%
Ph phase_1
1
25%

Phase Distribution

1

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
Phase 2Efficacy & side effects
1(33.3%)
Phase 4Post-market surveillance
1(33.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(3)
Terminated(1)

Detailed Status

Completed3
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
75.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (33.3%)
Phase 21 (33.3%)
Phase 41 (33.3%)

Trials by Status

completed375%
terminated125%

Recent Activity

0 active trials
Showing 4 of 4
completedphase_1

The Effects Diflunisal on the Levels of BMS-986165 in Healthy Participants

NCT04113668
terminatedphase_4

Pilot Study of Diflunisal in HIV-infected Adults

NCT01676363
completedphase_2

The Effect of Diflunisal on Familial Amyloidosis

NCT00294671
completed

The Effect of Diflunisal on Familial Transthyretin Amyloidosis

NCT01432587

Clinical Trials (4)

Showing 4 of 4 trials
NCT04113668Phase 1

The Effects Diflunisal on the Levels of BMS-986165 in Healthy Participants

Completed
NCT01676363Phase 4

Pilot Study of Diflunisal in HIV-infected Adults

Terminated
NCT00294671Phase 2

The Effect of Diflunisal on Familial Amyloidosis

Completed
NCT01432587

The Effect of Diflunisal on Familial Transthyretin Amyloidosis

Completed

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4